(Q40767845)

23 September 2017

title

Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992. (English)

1 reference

23 September 2017

0 references

1 reference

Cotterill SJ

1

1 reference

23 September 2017

Pearson AD

2

1 reference

23 September 2017

Pritchard J

3

1 reference

23 September 2017

Foot AB

4

1 reference

23 September 2017

Roald B

5

1 reference

23 September 2017

Kohler JA

6

1 reference

23 September 2017

Imeson J

7

1 reference

23 September 2017

publication date

1 May 2000

1 reference

European Journal of Cancer

23 September 2017

published in

1 reference

23 September 2017

volume

36

1 reference

23 September 2017

issue

7

1 reference

23 September 2017

page(s)

901-908

1 reference

Childhood cancer in Britain: the National Registry of Childhood Tumours and incidence rates 1978-1987.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Neuroblastoma. Effect of genetic factors on prognosis and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Abnormalities of chromosome 1p in human neuroblastoma tumors and cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Allelic loss of chromosome 1 and additional chromosome 17 material are both unfavourable prognostic markers in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Gain of chromosome arm 17q predicts unfavourable outcome in neuroblastoma patients. U.K. Children's Cancer Study Group and the U.K. Cancer Cytogenetics Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Neuroblastoma, its natural history and prognosis: a study of 487 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Factors influencing survival of children with nonmetastatic neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Serum lactate dehydrogenase in childhood neuroblastoma. A Pediatric Oncology Group recursive partitioning study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Single-agent ifosfamide in patients with recurrent neuroblastoma (ENSG study 2). European Neuroblastoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Ifosfamide in previously untreated disseminated neuroblastoma. Results of Study 3A of the European Neuroblastoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Very-high-dose cisplatin and etoposide in children with untreated advanced neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Advanced neuroblastoma: improved response rate using a multiagent regimen (OPEC) including sequential cisplatin and VM-26.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

A comparison of four staging systems for localized and regional neuroblastoma: a report from the Childrens Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Late recurrence of neuroblastoma: a report of five cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Disseminated neuroblastoma (stage IV and IV-S) in the first year of life. Outcome related to age and stage. Italian Cooperative Group on Neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Prognostic factors in metastatic neuroblastoma. A multivariate analysis of 182 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Detection of bone marrow infiltration by neuroblastoma in clinical practice: how far have we come?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Gender and survival in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Stage and urinary catecholamine metabolite excretion in neuroblastoma. European Neuroblastoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2800%2900058-7

7 January 2021

10.1016/S0959-8049(00)00058-7

Identifiers

DOI

1 reference

23 September 2017

1 reference